Impact of time to therapy and presence of collaterals on the efficacy of FX06 in acute ST elevation myocardial infarction: A substudy of the F.I.R.E., the Efficacy of FX06 in the prevention of myocardial reperfusion injury trial

EuroIntervention

Volumn 5, Issue 8, 2010, Pages 946-952

  Hallén, Jonas ^a   Petzelbauer, Peter ^b   Schwitter, Jürg ^c   Geudelin, Bernard ^d   Buser, Peter ^e   Atar, Dan ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d Fibrex Medical Research and Development GmbH   (Austria)

^e UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Cardiac magnetic resonance imaging; Primary percutaneous coronary intervention; Reperfusion injury; ST elevation myocardial infarction

Indexed keywords

FIBRIN DERIVATIVE; FX 06; PLACEBO; TROPONIN I; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CARDIOVASCULAR AGENT; FIBRIN DEGRADATION PRODUCT; FIBRINOGEN BBETA (15 42); FIBRINOGEN BBETA (15-42); PEPTIDE FRAGMENT;

ADULT; ARTICLE; COLLATERAL CIRCULATION; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEART INFARCTION SIZE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE NECROSIS; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; RANDOMIZED CONTROLLED TRIAL; REPERFUSION INJURY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TIME; TIME TO THERAPY; TREATMENT DURATION; AGED; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY BLOOD FLOW; DRUG ADMINISTRATION; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; HEART STROKE VOLUME; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BIOLOGICAL MARKERS; CARDIOVASCULAR AGENTS; COLLATERAL CIRCULATION; CORONARY CIRCULATION; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; INJECTIONS, INTRAVENOUS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; PEPTIDE FRAGMENTS; STROKE VOLUME; TIME FACTORS; TREATMENT OUTCOME; TROPONIN I; VENTRICULAR FUNCTION, LEFT;

EID: 77957037534     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJV5I8A159     Document Type: Article

References (26)

1. Atar D, Petzelbauer P, Schwitter J, Huber K, Rensing B, Kasprzak JD, Butter C, Grip L, Hansen PR, Süselbeck T, Clemmensen PM, Marin-Galiano M, Geudelin B, Buser PT; F.I.R.E. Investigators. Effect of intravenous FX06 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction results of the F.I.R.E. (Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury) trial. J Am Coll Cardiol 2009;53:720-729.
2. Hausenloy DJ, Yellon DM. Time to take myocardial reperfusion injury seriously. N Engl J Med 2008;359:518-520.
3. Braunwald E, Kloner RA. Myocardial reperfusion: a double-edged sword? J Clin Invest 1985;76:1713-1719.
4. Jennings RB, Sommers HM, SMYTH GA, FLACK HA, LINN H. Myocardial necrosis induced by temporary occlusion of a coronary artery in the dog. Arch Pathol 1960;70:68-78.
5. Lucchesi BR, Werns SW, Fantone JC. The role of the neutrophil and free radicals in ischemic myocardial injury. J Mol Cell Cardiol 1989;21:1241-1251. (Pubitemid 20046099)
6. Hansen PR. Role of neutrophils in myocardial ischemia and reperfusion. Circulation 1995;91:1872-1885.
7. Vinten-Johansen J. Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury. Cardiovasc Res 2004;61:481-497. (Pubitemid 38210154)
8. Zacharowski K, Zacharowski P, Reingruber S, Petzelbauer P. Fibrin (ogen) and its fragments in the pathophysiology and treatment of myocardial infarction. J Mol Med 2006;84:469-477. (Pubitemid 43801325)
9. Kloner RA, Forman MB, Gibbons RJ, Ross AM, Alexander RW, Stone GW. Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trial. Eur Heart J 2006;27:2400-2405. (Pubitemid 44522145)
10. Atar D, Huber K, Rupprecht HJ, Kopecky SL, Schwitter J, Theek C, Brandl K, Henning R, Geudelin B. Rationale and design of the "F.I.R.E." study. A multicenter, double-blind, randomized, placebo-controlled study to measure the effect of FX06 (a fibrin-derived peptide Bbeta (15-42)) on ischemia-reperfusion injury in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Cardiology 2007;108:117-123.
11. Dirksen MT, Laarman G, van 't Hof AW, Guagliumi G, Tonino WA, Tavazzi L, Duncker DJ, Simoons ML; PARI-MI Investigators (Protect Against Reperfusion Injury with ITF-1697 in acute Myocardial Infarction). The effect of ITF-1697 on reperfusion in patients undergoing primary angioplasty. Safety and efficacy of a novel tetrapeptide, ITF-1697. Eur Heart J 2004;25:392-400.
12. Wall TC, Califf RM, Blankenship J, Talley JD, Tannenbaum M, Schwaiger M, Gacioch G, Cohen MD, Sanz M, Leimberger JD. Intravenous Fluosol in the treatment of acute myocardial infarction. Results of the Thrombolysis and Angioplasty in Myocardial Infarction 9 Trial. TAMI 9 Research Group. Circulation 1994;90:114-120.
13. Faxon DP, Gibbons RJ, Chronos NA, Gurbel PA, Sheehan F. The effect of blockade of the CD11/CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty: the results of the HALT-MI study. J Am Coll Cardiol 2002;40:1199-1204.
14. Baran KW, Nguyen M, McKendall GR, Lambrew CT, Dykstra G, Palmeri ST, Gibbons RJ, Borzak S, Sobel BE, Gourlay SG, Rundle AC, Gibson CM, Barron HV; Limitation of Myocardial Infarction Following Thrombolysis in Acute Myocardial Infarction (LIMIT AMI) Study Group. Double-blind, randomized trial of an anti-CD18 antibody in conjunction with recombinant tissue plasminogen activator for acute myocardial infarction: limitation of myocardial infarction following thrombolysis in acute myocardial infarction (LIMIT AMI) study. Circulation 2001;104:2778-2783.
15. Wang QD, Pernow J, Sjoquist PO, Ryden L. Pharmacological possibilities for protection against myocardial reperfusion injury. Cardiovasc Res 2002;55:25-37. (Pubitemid 34618530)
16. Dirksen MT, Laarman GJ, Simoons ML, Duncker DJ. Reperfusion injury in humans: a review of clinical trials on reperfusion injury inhibitory strategies. Cardiovasc Res 2007;74:343-355. (Pubitemid 46693697)
17. Jolly SR, Kane WJ, Hook BG, Abrams GD, Kunkel SL, Lucchesi BR. Reduction of myocardial infarct size by neutrophil depletion: effect of duration of occlusion. Am Heart J 1986;112:682-690.
18. Williams FM, Kus M, Tanda K, Williams TJ. Effect of duration of ischaemia on reduction of myocardial infarct size by inhibition of neutrophil accumulation using an anti-CD18 monoclonal antibody. Br J Pharmacol 1994;111:1123-1128. (Pubitemid 24148780)
19. Romson JL, Hook BG, Kunkel SL, Abrams GD, Schork MA, Lucchesi BR. Reduction of the extent of ischemic myocardial injury by neutrophil depletion in the dog. Circulation 1983;67:1016-1023.
20. Simpson PJ, Mitsos SE, Ventura A, Gallagher KP, Fantone JC, Abrams GD, Schork MA, Lucchesi BR. Prostacyclin protects ischemic reperfused myocardium in the dog by inhibition of neutrophil activation. Am Heart J 1987;113:129-137.
21. Gröger M, Pasteiner W, Ignatyev G, Matt U, Knapp S, Atrasheuskaya A, Bukin E, Friedl P, Zinkl D, Hofer-Warbinek R, Zacharowski K, Petzelbauer P, Reingruber S. Peptide Bbeta (15-42) preserves endothelial barrier function in shock. PLoS One 2009;4:e5391.
22. Nijveldt R, Beek AM, Hofman MB, Umans VA, Algra PR, Spreeuwenberg MD, Visser CA, van Rossum AC Late Gadolinium-Enhanced Cardiovascular Magnetic Resonance Evaluation of Infarct Size and Microvascular Obstruction in Optimally Treated Patients after Acute Myocardial Infarction. J Cardiovasc Magn Reson 2007;9:765-770. (Pubitemid 47463905)
23. Mazzocchi F. Complexity in biology. Exceeding the limits of reductionism and determinism using complexity theory. EMBO Rep 2008;9:10-14.
24. Piot C, Croisille P, Staat P, Thibault H, Rioufol G, Mewton N, Elbelghiti R, Cung TT, Bonnefoy E, Angoulvant D, Macia C, Raczka F, Sportouch C, Gahide G, Finet G, André-Fouët X, Revel D, Kirkorian G, Monassier JP, Derumeaux G, Ovize M. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 2008;359:473-481.
25. Bates E, Bode C, Costa M, Gibson CM, Granger C, Green C, Grimes K, Harrington R, Huber K, Kleiman N, Mochly-Rosen D, Roe M, Sadowski Z, Solomon S, Widimsky P. Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. Circulation 2008;117:886-896. (Pubitemid 351272586)
26. Burns RJ, Gibbons RJ, Yi Q, Roberts RS, Miller TD, Schaer GL, Anderson JL, Yusuf S; CORE Study Investigators. The relationships of left ventricular ejection fraction, end-systolic volume index and infarct size to six-month mortality after hospital discharge following myocardial infarction treated by thrombolysis. Journal of the American College of Cardiology 2002;39:30-36. (Pubitemid 34059858)